Opyl : 2021 AGM Presentation 18 November 2021

For personal use only

Annual GeneralCompanyMeeting 2021

(ASX:OPL)Introduction

www.opyl.ai ASX:OPL

September 2021

For personal use only

Disclaimer

This presentation has been prepared by Opyl Limited ("Opyl"). Each recipient of this presentation is deemed to have agreed to accept the qualifications, limitations and disclaimers set out below.

None of Opyl, its subsidiaries or respective directors, officers, employees, advisers or representatives ("Beneficiaries") make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation, including any forecast or prospective information. The forward-looking statements included in this presentation involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, the Beneficiaries. Actual future events may vary materially from the forward-looking statements and the assumptions on which those statements are based. Given these uncertainties, you are cautioned to not place undue reliance on such forward-looking statements.

This presentation is a general overview only and does not purport to contain all the information that may be required to evaluate an investment in Opyl. The information in this presentation is provided personally to the recipient as a matter of interest only. It does not amount to an express or implied recommendation with respect to any investment in Opyl, nor does it constitute financial product advice. The recipient, intending investors and respective advisers should: conduct their own independent review, investigations and analysis of Opyl and of the information contained or referred to in this presentation; and/or seek professional advice as to whether an investment in Opyl is appropriate for them, having regard to their personal objectives, risk profile, financial situation and needs. Nothing in this presentation is or is to be taken to be an offer, invitation or other proposal to subscribe for shares in Opyl. Except insofar as liability under any law cannot be excluded, none of the Beneficiaries shall have any responsibility for the information contained in this presentation or in any other way for errors or omissions (including responsibility to any persons by reason of negligence).

www.opyl.ai

For personal use only

What does Opyl do

Opyl is a healthcare data optimisation company

Opyl's purpose is to match eligible, motivated patients to clinical trials

anywhere in the world, solving one of the most significant problems in clinical research

Opyl leverages big data and applies AI to design smarter clinical trials

with a higher probability of success, reducing risk, cost and 'failures' in medical research

Opyl's vision is for clinical research to deliver more value, deliver a better return on investment for medical researchers and investors, and therefore, provide more patients with access to more life saving, and life changing therapies

For personal use only

What's the problem Opyl's trying to solve

Patient recruitment to clinical trials is a key determinant of trial success1

86% of clinical trials fail to reach recruitment targets2, costing hundreds of millions of dollars3 in trial budget blow outs each year

The one who pays the real price, is the patient

considerable amount of 'failure' and waste of financial resources can be prevented

with the application of big data, digital tools and predictive analytics

To design smarter trials and to recruit patients and volunteers more efficiently

Source:1.Grant D.HuangaJoncaBullbKellyJohnston McKeecElizabethMahondBethHarpereJamie N.RobertsfClinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. Contemporary Clinical Trials. Vol 66, March 2018. pg 74-79. Source 2. DL. Anderson. A Guide to Patient Recruitment. Centrewatch/Thompson Healthcare. Boston USA. 2001.

Source 3. R.J. Bielski, R.B. Lydiard Therapeutic trial participants: where do we find them and what does it cost? Psychopharmacol. Bull., 33 (1997), pp. 75-78

For personal use only

Company snapshot

Digital health company delivering AI-enabled clinical trial efficiency solutions

3 platforms in development - 2 on market (MVP) generating early stage revenue Customers: global biopharma, medtech, govt & CRO/sites (US and APAC) Based in Melbourne, Australia with 7.8 FTE

$1.55m Nov 2021